Difference between revisions of "ALK inhibitors"

From Libre Pathology
Jump to navigation Jump to search
 
Line 11: Line 11:
*[[ALK positive lung cancer]].
*[[ALK positive lung cancer]].
*[[ALK translocation renal cell carcinoma]].
*[[ALK translocation renal cell carcinoma]].
*[[ROS1-rearranged non-small cell lung carcinoma]].


==References==
==References==

Latest revision as of 02:19, 31 December 2019

ALK inhibitors are a group of drugs that act on tumours with ALK rearrangements.

See also

References

  1. Honda, K.; Kadowaki, S.; Kato, K.; Hanai, N.; Hasegawa, Y.; Yatabe, Y.; Muro, K. (Feb 2019). "Durable response to the ALK inhibitor alectinib in inflammatory myofibroblastic tumor of the head and neck with a novel SQSTM1-ALK fusion: a case report.". Invest New Drugs. doi:10.1007/s10637-019-00742-2. PMID 30790150.
  2. Pal, SK.; Bergerot, P.; Dizman, N.; Bergerot, C.; Adashek, J.; Madison, R.; Chung, JH.; Ali, SM. et al. (07 2018). "Responses to Alectinib in ALK-rearranged Papillary Renal Cell Carcinoma.". Eur Urol 74 (1): 124-128. doi:10.1016/j.eururo.2018.03.032. PMID 29685646.